A statement released earlier today by Cantor Fitzgerald about Redx Pharma Plc (LON:REDX) maintains the target price at 105.00GBX
- Updated: September 26, 2016
Having a price of 60.50GBX, Redx Pharma Plc (LON:REDX) traded 14.80% higher on the day. With the last stock price up 80.15% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. REDX has recorded a 50-day average of 31.10GBX and a two hundred day average of 32.50GBX. Trade Volume was up over the average, with 1,267,982 shares of REDX changing hands over the typical 230,125
Reporting a potential upside of 0.74%, Cantor Fitzgerald hold steady the price target of Redx Pharma Plc (LON:REDX) at 105.00GBX
On 9/19/2016, Cantor Fitzgerald released a statement about Redx Pharma Plc (LON:REDX) maintained the target price at 105.00GBX that suggested an upside of 1.92%.
Recent Performance Chart
Redx Pharma Plc has with a one year low of 23.00GBX and a one year high of 102.88GBX and has a market capitalization of 0 GBX.
General Company Details For Redx Pharma Plc (LON:REDX)
Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton's Tyrosine Kinase (BTK), which has reached candidate nomination stage. The Company's oncology research activity also include Porcupine program, Colony Stimulating Factor-1 receptor (CSF-1) program, Indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitor and Pan-Raf inhibitor. The Company's anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX003, is a class of antibiotic acting through the type II bacterial topoisomerases. It is also evaluating BTK inhibitor for immunological disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.